Dr. Komrokji on Optimizing MDS Management

Rami S. Komrokji, MD
Published: Tuesday, Apr 14, 2015



Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses optimizing the management of treatment for myelodysplastic syndrome (MDS).

Because there are limited options approved for MDS, it is important that oncologists optimize treatment in order to achieve the best results, says Komrokji.

Biomarkers can be used to best select which treatment should be used first for MDS. It is also important to be familiar with the management, toxicities and response timelines for each treatment. This way, if a treatment is not working well, the physician can switch to a more optimal treatment regimen.

Komrokji says it is also important to determine the optimal time, if at all, to conduct a transplant. ​

SELECTED
LANGUAGE


Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses optimizing the management of treatment for myelodysplastic syndrome (MDS).

Because there are limited options approved for MDS, it is important that oncologists optimize treatment in order to achieve the best results, says Komrokji.

Biomarkers can be used to best select which treatment should be used first for MDS. It is also important to be familiar with the management, toxicities and response timelines for each treatment. This way, if a treatment is not working well, the physician can switch to a more optimal treatment regimen.

Komrokji says it is also important to determine the optimal time, if at all, to conduct a transplant. ​




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x